BBT001 subcutaneous / Bambusa Therapeutics - LARVOL DELTA

Bambusa Therapeutics Initiates Subcutaneous Dosing of BBT001 in Atopic Dermatitis… (PRNewswire) - "The SC cohort is part of Bambusa's global Phase 1 BBT001-001 study and is evaluating 12 weeks of treatment with SC BBT001 in biologic-naïve patients with moderate-to-severe AD. The cohort is currently enrolling up to 45 patients across the United States, Australia, Europe and New Zealand. Patients will receive five doses of BBT001 at either 360 mg or 720 mg, or the placebo, administered subcutaneously...The primary endpoints are safety and tolerability. Secondary endpoints include pharmacokinetics, including half-life, and immunogenicity."

Trial status • Atopic Dermatitis